It was recently shown that chemotherapeutic agents, such as anthracyclines, can induce an immunogenic form of apoptotic cell death, 13, 14 which stimulates the induction of an adaptive immune response ...
Dynavax’s association with Glaxo goes back to 2008 when the companies had entered into a research and development collaboration and license agreement for the discovery, development and ...
BERKELEY, CA--Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors (TLR) 7 and 9 ...
S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). Background: The potent TLR-9 agonist MGN1703, a synthetic ...
Dynavax Technologies Corporation and AstraZeneca have amended their existing Collaboration Agreement to accelerate the initiation of clinical development of AZD 1419, a proprietary second-generation ...
Dynavax Technologies Corporation ( DVAX) regained full rights to its pipeline candidate, DV1179, following the expiration of its collaboration agreement with GlaxoSmithKline ( GSK). Dynavax will now ...
Dynavax Technologies Corporation and AstraZeneca have amended their existing Collaboration Agreement to accelerate the initiation of clinical development of AZD 1419, a proprietary second-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback